1
|
Baudry AS, Delpuech M, Charton E, Hivert B, Carnot A, Ceban T, Dominguez S, Lemaire A, Aelbrecht-Meurisse C, Anota A, Christophe V. Association between emotional competence and risk of unmet supportive care needs in caregivers of cancer patients at the beginning of care. Support Care Cancer 2024; 32:302. [PMID: 38647710 DOI: 10.1007/s00520-024-08510-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Accepted: 04/15/2024] [Indexed: 04/25/2024]
Abstract
PURPOSE This cross-sectional study explored the associations between intrapersonal and interpersonal emotional competence (EC) and the unmet supportive care needs (SCN), anxiety, and depression of informal caregivers at the beginning of gastrointestinal or haematological cancer care, i.e. during chemotherapy and within 6 months after diagnosis. METHODS The participants completed a self-reported questionnaire, comprising the Short Profile of Emotional Competence (S-PEC), the SCN survey for partners and caregivers (SCNS-P&C), and the Hospital Anxiety and Depression Scale (HADS). Multivariate logistic regression models were performed to explore the influence of EC on unmet SCN and the presence of moderate/severe anxiety or depression. RESULTS Most of the 203 caregivers were women (n = 141, 69.80%) and the partners of patients (n = 148, 73.27%) suffering from gastrointestinal (n = 112, 55.17%) and haematological (n = 91, 44.83%) cancer. Only intrapersonal EC showed a significant influence out of all the dimensions of unmet SCN related to healthcare services and information (odds ratio (OR) = 0.35 [95%CI 0.19; 0.65]), emotional and psychological needs (OR = 0.43 [95%CI 0.25; 0.74]), work and social security (OR = 0.57 [95%CI 0.37; 0.88]), and communication and family support (OR = 0.61 [95%CI 0.39; 0.95]). A one-unit increase in the intrapersonal EC score significantly reduced the probability of anxiety (OR = 0.42, [95%CI 0.26; 0.68]) and depression (OR = 0.34, [95%CI 0.21; 0.55]). CONCLUSION Intrapersonal EC of caregivers is crucial to reduce the risk of unmet SCN, anxiety, and depression from the beginning of care. Identifying caregivers with lower intrapersonal EC may be necessary to increase vigilance from healthcare professionals and psychologists.
Collapse
Affiliation(s)
- Anne-Sophie Baudry
- Pôle Cancérologie Et Spécialités Médicales, Centre Hospitalier de Valenciennes, Valenciennes, France.
- Univ. Lille, CNRS, UMR 9193 - SCALab - Sciences Cognitives Et Sciences Affectives, 59000, Lille, France.
- Human and Social Sciences Department, Centre Léon Bérard, Lyon, France.
- Service d'oncologie, Centre Hospitalier de Valenciennes, Avenue Désandrouin - cs 50479, 59322, Valenciennes Cedex, France.
| | - Marion Delpuech
- Human and Social Sciences Department, Centre Léon Bérard, Lyon, France
| | - Emilie Charton
- Human and Social Sciences Department, Centre Léon Bérard, Lyon, France
- Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France
| | - Benedicte Hivert
- Service d'Onco-Hématologie, Hôpital Saint Vincent de Paul, GHICL, Lille, France
| | - Aurelien Carnot
- Pôle d'oncologie médicale, Centre Oscar Lambret, Lille, France
| | - Tatiana Ceban
- Service d'Oncologie, Centre Hospitalier de Dunkerque, Dunkerque, France
| | - Sophie Dominguez
- Service d'Onco-Hématologie, Hôpital Saint Vincent de Paul, GHICL, Lille, France
| | - Antoine Lemaire
- Pôle Cancérologie Et Spécialités Médicales, Centre Hospitalier de Valenciennes, Valenciennes, France
| | | | - Amelie Anota
- Human and Social Sciences Department, Centre Léon Bérard, Lyon, France
- Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France
- The French National Platform Quality of Life and Cancer, Lyon, France
| | - Veronique Christophe
- Univ. Lille, CNRS, UMR 9193 - SCALab - Sciences Cognitives Et Sciences Affectives, 59000, Lille, France
- Human and Social Sciences Department, Centre Léon Bérard, Lyon, France
- Université Claude Bernard Lyon 1, CRCL, UMR Mixte INSERM 1052-CNRS 5286, Lyon, France
| |
Collapse
|
2
|
Strobbe G, Gaboriau L, Abelé M, Villain A, Aelbrecht-Meurisse C, Carnot A, Le Deley MC, Léguillette C, Feutry F, Sakji I, Marliot G. Impact of histamine-2 antagonist shortage on the incidence of hypersensitivity reactions to paclitaxel: a reconsideration of premedication protocols in France (PACLIREACT Study). Eur J Clin Pharmacol 2023; 79:1229-1238. [PMID: 37438439 DOI: 10.1007/s00228-023-03536-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Accepted: 06/29/2023] [Indexed: 07/14/2023]
Abstract
PURPOSE An international shortage of ranitidine led to adjustments in premedication regimens for paclitaxel-based chemotherapy in early October 2019. In this study, we implemented and evaluated an anti-allergic protocol without histamine-2 antagonists (H2As) and aimed to assess the risk of hypersensitivity reactions (HSRs) to the different premedication regimens used. METHODS We conducted a single-center observational retrospective study of paclitaxel administrations (7173 administrations in 831 patients). Between January 2019 and December 2020, all allergies reported were recorded. A mixed logistic regression model was implemented to predict the risk of allergy at each injection and to account for repeated administration per patient. RESULTS A total of 27 HSRs occurred in 24 patients. No protective effect was observed for H2A when comparing paclitaxel injections with H2A premedication versus without H2A (OR = 1.12, p = 0.84). There was also no significant difference in risk of HSR for famotidine versus ranitidine (OR = 0.79, p = 0.78). However, the risk of HSRs was significantly lower for paclitaxel injections with corticosteroids than for those without (OR = 0.08, p = 0.03). In addition, the risk of HSR was significantly higher for the first, second, or third paclitaxel injections than for the subsequent injections (OR = 10.1, p < 0.001). CONCLUSION We did not find substantial evidence of an increased risk of HSR due to the absence of H2A in the premedication protocols for paclitaxel. Thus, in contrary to the existing literature on paclitaxel, our findings support the use of a premedication protocol without H2A.
Collapse
Affiliation(s)
- Geoffrey Strobbe
- Pole produits de santé, Service de pharmacie, Centre Oscar Lambret, 3, rue Frédéric Combemale, 59020, Cedex BP307, Lille, France.
| | - Louise Gaboriau
- Centre Régional de Pharmacovigilance, Service de pharmacologie, CHU, Lille, France
| | - Marie Abelé
- Pole produits de santé, Service de pharmacie, Centre Oscar Lambret, 3, rue Frédéric Combemale, 59020, Cedex BP307, Lille, France
| | - Alexandre Villain
- Pole produits de santé, Service de pharmacie, Centre Oscar Lambret, 3, rue Frédéric Combemale, 59020, Cedex BP307, Lille, France
| | | | - Aurélien Carnot
- Pole d'oncologie médicale, Centre Oscar Lambret, Lille, France
| | | | | | - Frédéric Feutry
- Pole produits de santé, Service de pharmacie, Centre Oscar Lambret, 3, rue Frédéric Combemale, 59020, Cedex BP307, Lille, France
| | - Ilyes Sakji
- Pole produits de santé, Service de pharmacie, Centre Oscar Lambret, 3, rue Frédéric Combemale, 59020, Cedex BP307, Lille, France
| | - Guillaume Marliot
- Pole produits de santé, Service de pharmacie, Centre Oscar Lambret, 3, rue Frédéric Combemale, 59020, Cedex BP307, Lille, France
| |
Collapse
|
3
|
Aelbrecht-Meurisse C, Ryckewaert T, Pannier D, Gamblin V, Garcia V, Aelbrecht S, Penel N. [Withholding or withdrawing life-sustaining treatments in acute oncology situations: History and regulatory aspects in France]. Bull Cancer 2021; 108:415-423. [PMID: 33678409 DOI: 10.1016/j.bulcan.2020.11.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Revised: 10/28/2020] [Accepted: 11/20/2020] [Indexed: 10/22/2022]
Abstract
The management of oncology patients, especially hospitalized patients, can lead to almost daily discussions regarding therapeutic limitations. Here, we review the history and propose a summary of the texts framing the notion of "withholding and withdrawing life-sustaining treatment" in oncology practice in France. This decision is regulated by the Claeys-Léonetti Law of February 2, 2016 recommending a collegial discussion and its documentation in the medical record. The decision to withhold or withdraw life-sustaining treatments is the subject of discussion between the patient, his physicians and his family and may take place at any time during his management. The work of intensive-care physicians provides many useful recommendations for acute oncology situations, however articles specific for oncology practice are scarce; this is a topic that oncologists must take up.
Collapse
Affiliation(s)
| | - Thomas Ryckewaert
- Centre Oscar Lambret, département d'oncologie médicale, 3, rue Frédéric Combemale, 59000 Lille, France
| | - Diane Pannier
- Centre Oscar Lambret, département d'oncologie médicale, 3, rue Frédéric Combemale, 59000 Lille, France
| | - Vincent Gamblin
- Centre Oscar Lambret, département de soins palliatifs, 3, rue Frédéric Combemale, 59000 Lille, France
| | - Vincent Garcia
- Centre Oscar Lambret, département d'anesthésie-réanimation, 3, rue Frédéric Combemale, 59000 Lille, France
| | - Stéphane Aelbrecht
- EHPAD Les Myosotis, 160, rue Augustin Tirmont, 59283 Raimbeaucourt, France
| | - Nicolas Penel
- Centre Oscar Lambret, département d'oncologie médicale, 3, rue Frédéric Combemale, 59000 Lille, France
| |
Collapse
|
4
|
Marcant P, Moreau A, Da Silva A, Aelbrecht-Meurisse C, Staumont-Sallé D. Central venous access device-associated contact dermatitis in patients with cancer: The utility of extensive screening patch tests. Contact Dermatitis 2020; 84:348-350. [PMID: 33210314 DOI: 10.1111/cod.13744] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Revised: 11/09/2020] [Accepted: 11/13/2020] [Indexed: 11/28/2022]
Affiliation(s)
- Pierre Marcant
- CHU de Lille, Service de dermatologie, Lille, France.,University of Lille, Lille, France
| | | | - Aline Da Silva
- CH de Valenciennes, Service d'oncologie, Valenciennes, France
| | | | | |
Collapse
|